Collectively, these data suggest that increasing p-GR at the sites induced by neurotrophic signaling could improve cognition in AD subjects without impacting cortisol-activating sites, presenting a novel opportunity for therapeutic intervention. This evidence concerns the gene NR3C1 and Alzheimer disease.